Richmond Pharmacology presents latest Thorough QT study at the ASCPT 2014 Annual Meeting

Posted:
3
March 2014

Moxifloxacin is used as a probe to confirm assay sensitivity in thorough electrocardiogram (ECG) studies. A meal shortens the QT interval and in some instances it is desirable to use moxifloxacin after a meal which may affect PK or PD or both; however there is no published data.Based on a recent peer-reviewed paper published in January 2014 in the British Journal of Clinical Pharmacology Richmond Pharmacology will present its latest findings as an encore poster presentation at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), taking place 18th to 22nd March, in Atlanta, Georgia.Join Richmond Pharmacology s Dr Jorg Taubel on 21st March between 11h45 and 13h15 (poster number EII-001) for insight into this new area of research.Read Full PaperView Meeting Program

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more